☆ 4.4 Article

Disease characteristics, pathogenesis, and treatment controversies of axial psoriatic arthritis

JOINT BONE SPINE (2024)

Related references

Note: Only part of the references are listed.

Editorial Material Rheumatology

Similarities and differences between axial spondyloarthritis and axial psoriatic arthritis

Weijie Wang et al.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Add to Collection

Article Medicine, Research & Experimental

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials

Arthur Kavanaugh et al.

Summary: This study suggests that psoriatic arthritis with axial involvement (axPsA) and radiographic axial spondyloarthritis (r-axSpA) may be distinct disorders with different clinical manifestations and genetic associations. Additionally, these disorders may respond differently to therapies. The findings contribute to our understanding of the potential genetic and molecular differences between axPsA and r-axSpA.

ADVANCES IN THERAPY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms

Denis Poddubnyy

Summary: A significant number of PsA patients exhibit symptoms of inflammatory axial involvement, requiring clinical and laboratory evaluation as well as axial imaging. Treatment for confirmed axial PsA includes non-pharmacologic and pharmacologic methods such as non-steroidal anti-inflammatory drugs, tumor necrosis factor, interleukin 17, and Janus kinase inhibitors.

DRUGS (2023)

Add to Collection

Review Rheumatology

Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Ying-Ying Leung et al.

Summary: The objective of this study was to provide evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of PsA for the revised 2021 GRAPPA treatment recommendations. Evidence was derived from new RCTs and recommendations were made for different patient groups based on their treatment history and response. Different classes of therapeutic options were strongly recommended for different patient groups.

JOURNAL OF RHEUMATOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

MRI Findings in Axial Psoriatic Spondylarthritis

Loredana Sabina Pascu et al.

Summary: Psoriatic arthritis is a clinically significant disease with a high prevalence and overlapping symptoms with other spondylarthritis disorders. Understanding the MRI manifestations and implementing a multidisciplinary strategy is crucial for effective management.

DIAGNOSTICS (2023)

Add to Collection

Article Rheumatology

Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA

Anne Constanze Regierer et al.

Summary: This study compared the differences between psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The results showed that there were significant differences between patients with axial involvement in PsA (axPsA) and patients with axSpA accompanied by psoriasis (axSpA+pso), regardless of whether it was clinically or radiologically defined.

RMD OPEN (2023)

Add to Collection

Article Rheumatology

Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry

Adrian Ciurea et al.

Summary: This study compared the characteristics of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), and found differences in demographic and clinical features between the two groups, but a similar disease burden.

RMD OPEN (2023)

Add to Collection

Editorial Material Rheumatology

Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes

Fabian Proft et al.

RMD OPEN (2023)

Add to Collection

Article Rheumatology

Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts

Manouk de Hooge et al.

Summary: This study aimed to examine radiographic axial damage of the sacroiliac joints and spine in patients with psoriatic arthritis (PsA) and spondyloarthritis (SpA) in private and academic Belgian practices. The data comparison between the two patient groups found that patients with SpA tend to have more severe spinal damage compared to those with PsA. In patients with PsA, the cervical spine is more often affected, while in patients with SpA, the location of syndesmophytes is more evenly distributed.

RMD OPEN (2023)

Add to Collection

Editorial Material Rheumatology

No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?

Juergen Braun et al.

Summary: Three monoclonal antibodies targeting interleukin-23 have been approved for psoriasis treatment, with two also approved for psoriatic arthritis. However, they have shown to be ineffective in axial spondyloarthritis and may be due to generic effects rather than specific inflammation.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Laura C. Coates et al.

Summary: The study demonstrated that guselkumab significantly improved joint and skin manifestations as well as physical function in patients with TNFi-IR PsA. A higher proportion of patients in the guselkumab group achieved ACR20 and other key secondary endpoints compared to the placebo group, with 58% of ACR20 response in the guselkumab group at week 48.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

Andrew Ostor et al.

Summary: The study found that treatment with risankizumab resulted in significant improvements in key disease outcomes for patients with PsA who were Bio-IR and/or csDMARD-IR, and was well tolerated.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Review Rheumatology

Psoriatic Spondylitis: A Disease Manifestation in Debate Evidences to Know for the Clinical Rheumatologist

Henning K. Zeidler

Summary: With the development of classification criteria, the terminology and categorization of axial manifestations associated with psoriasis have become more clear. Studies have shown that axial disease in patients with psoriatic arthritis differs demographically, genetically, clinically, and radiographically from ankylosing spondylitis with or without psoriasis.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings

Pamela Diaz et al.

Summary: Prevalence of inflammatory and structural lesions in patients with psoriatic disease can be assessed using whole spine MRI, but their correlation with clinical features and axSpA classification criteria is poor.

RMD OPEN (2022)

Add to Collection

Editorial Material Rheumatology

Axial psoriatic arthritis: New entity or clinical form only?

Daniel Wendling et al.

JOINT BONE SPINE (2022)

Add to Collection

Article Rheumatology

Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis

Timothy S. H. Kwok et al.

Summary: Isolated axial PsA and AS with psoriasis are relatively uncommon. HLA-B*27 positivity is associated with isolated axial PsA and may predict the development of peripheral disease. Isolated axial PsA is associated with better functional status. Isolated axial PsA appears clinically distinct from isolated axial AS with psoriasis.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?

Fabiola Atzeni et al.

Summary: IL-23 plays a protective role against bacterial and fungal infections, but its dysregulation can lead to inflammatory diseases. Drugs targeting IL-23 have shown excellent efficacy and safety in treating PsA, but lack the same efficacy in AS, with the reasons still unknown.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

Add to Collection

Article Rheumatology

Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry

Xabier Michelena et al.

Summary: This study compared the clinical and radiographical characteristics of axial psoriatic arthritis (PsA) with ankylosing spondylitis (AS) with psoriasis. It found that axial PsA is predominantly HLA-B27 negative and has different manifestations compared to AS with psoriasis. There is great heterogeneity in the definition of axial PsA from a clinical and imaging perspective.

RMD OPEN (2022)

Add to Collection

Article Rheumatology

Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial

Philip J. Mease et al.

Summary: This study assessed the efficacy and safety of risankizumab in psoriatic arthritis (PsA) patients over 76 weeks. The results showed that risankizumab significantly improved joint and skin symptoms in PsA patients compared to placebo, and these improvements were sustained long term. Risankizumab was well tolerated with no new safety findings over the 76-week period.

RHEUMATOLOGY AND THERAPY (2022)

Add to Collection

Article Medicine, Research & Experimental

Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

Dafna D. Gladman et al.

Summary: This study aims to evaluate the efficacy of guselkumab in reducing axial symptoms and inflammation in patients with active PsA.

TRIALS (2022)

Add to Collection

Article Medicine, General & Internal

Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy

Hyoun-Ah Kim et al.

Summary: This study investigated the clinical characteristics of PsA patients in Korea and found that asymmetric oligoarthritis was the most common manifestation, and psoriatic spondylitis was common among Korean PsA patients.

JOURNAL OF KOREAN MEDICAL SCIENCE (2022)

Add to Collection

Article Rheumatology

Efficacy and Safety of Guselkumab, an Interleukin-23p 19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis

Iain B. McInnes et al.

Summary: In biologic-naive patients with psoriatic arthritis, treatment with guselkumab for one year demonstrated sustained improvements in clinical efficacy, joint and skin symptoms, and physical function, as well as maintaining low levels of radiographic progression, providing a favorable risk-benefit profile.

ARTHRITIS & RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Xenofon Baraliakos et al.

Summary: The MAXIMISE trial demonstrated that secukinumab significantly improved axial disease symptoms in patients with PsA, particularly those with inadequate response to NSAIDs.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

IL-23 and axial disease: do they come together?

Philip Mease et al.

Summary: IL-23 plays a key role in the pathogenesis of spondyloarthritides, but the efficacy of IL-23 inhibition varies in different types of spondylitis, requiring further research.

RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies

Dennis McGonagle et al.

Summary: The study confirmed the efficacy of guselkumab in treating enthesitis, especially in resolving enthesitis and improving disease activity in patients. The results showed that guselkumab could continuously improve the condition of enthesitis and may have a positive impact on patient outcomes.

RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study

D. Benavent et al.

Summary: In this worldwide study, axial PsA was defined as a unique phenotype by rheumatologists, with disease features falling between axSpA and pure pPsA.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)

Add to Collection

Article Rheumatology

Axial Psoriatic Arthritis

Dafna D. Gladman

Summary: The prevalence of axial psoriatic arthritis (axPsA) is estimated at 40-50%, and recent studies suggest it has distinct features from ankylosing spondylitis. Due to the lack of a widely accepted definition of axPsA, designing therapeutic trials for this type of PsA has been challenging, but some recent trials indicate that treatments effective for peripheral arthritis may also be effective for axPsA.

CURRENT RHEUMATOLOGY REPORTS (2021)

Add to Collection

Review Immunology

Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis

Dennis McGonagle et al.

Summary: IL-23 plays a crucial role in spondyloarthritis, with implications in the genetic basis, disease progression and treatment efficacy. However, further studies are necessary to determine the specific effects and mechanisms of IL-23 in different disease sites.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Rheumatology

Axial involvement in psoriatic arthritis: An update for rheumatologists

Denis Poddubnyy et al.

Summary: Psoriatic arthritis (PsA) is a chronic, inflammatory musculoskeletal disease with heterogeneous characteristics, and axial involvement can lead to complications in management and treatment decisions. The lack of agreed-upon classification and diagnostic criteria for axial PsA complicates the approach to this subset of patients.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)

Add to Collection

Review Rheumatology

Axial Psoriatic Arthritis A Distinct Clinical Entity in Search of a Definition

Xabier Michelena et al.

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2020)

Add to Collection

Review Rheumatology

The many faces of psoriatic arthritis: their genetic determinism

Robert Winchester et al.

RHEUMATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Philip J. Mease et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Atul Deodhar et al.

LANCET (2020)

Add to Collection

Editorial Material Rheumatology

Axial spondyloarthritis: coming of age

Helena Marzo-Ortega

RHEUMATOLOGY (2020)

Add to Collection

Article Rheumatology

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials

Philip S. Helliwell et al.

RMD OPEN (2020)

Add to Collection

Review Rheumatology

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies

Dennis G. McGonagle et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

Add to Collection

Review Rheumatology

Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different?

Vinod Chandran

CURRENT OPINION IN RHEUMATOLOGY (2019)

Add to Collection

Article Rheumatology

Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression

Richard James Cuthbert et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

Add to Collection

Article Rheumatology

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Philip J. Mease et al.

JOURNAL OF RHEUMATOLOGY (2018)

Add to Collection

Review Rheumatology

Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison

Joy Feld et al.

NATURE REVIEWS RHEUMATOLOGY (2018)

Add to Collection

Review Allergy

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis

Andrew Blauvelt et al.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)

Add to Collection

Article Rheumatology

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

Arthur Kavanaugh et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

Add to Collection

Article Rheumatology

IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis

Eric Gracey et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

Add to Collection

Article Rheumatology

Interleukin-23-Dependent/T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice

Annika Reinhardt et al.

ARTHRITIS & RHEUMATOLOGY (2016)

Add to Collection

Review Immunology

HLA-B27

Paul Bowness

ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)

Add to Collection

Article Rheumatology

Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells

Peggy Jacques et al.

ANNALS OF THE RHEUMATIC DISEASES (2014)

Add to Collection

Article Rheumatology

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Christopher Ritchlin et al.

ANNALS OF THE RHEUMATIC DISEASES (2014)

Add to Collection

Article Biochemistry & Molecular Biology

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells

Jonathan P. Sherlock et al.

NATURE MEDICINE (2012)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Imaging the spine in arthritis-a pictorial review

Anne Grethe Jurik

INSIGHTS INTO IMAGING (2011)

Add to Collection

Article Rheumatology

Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis

Vinod Chandran et al.

JOURNAL OF RHEUMATOLOGY (2010)

Add to Collection

Article Rheumatology

Validity of the Bath Ankylosing Spondylitis Disease Activity Index for the Evaluation of Disease Activity in Axial Psoriatic Arthritis

Jose Luis Fernandez-Sueiro et al.

ARTHRITIS CARE & RESEARCH (2010)

Add to Collection

Article Rheumatology

Axial Psoriatic Arthritis: Update on a Longterm Prospective Study

Vinod Chandran et al.

JOURNAL OF RHEUMATOLOGY (2009)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Psoriatic arthritis and rheumatoid arthritis: Findings in contrast-enhanced MRI

Helmut Schoelinast et al.

AMERICAN JOURNAL OF ROENTGENOLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.